文献速递湿疹皮炎与荨麻疹自身免疫性与大疱性皮肤病

度普利尤单抗治疗慢性痒疹与慢性特发性瘙痒的疗效:当前证据的系统综述及应答预测因素分析

Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-05-31

本研究通过系统文献综述评估度普利尤单抗对慢性痒疹(CP)和慢性特发性瘙痒(CIP)患者瘙痒及皮肤表现的疗效,并探索应答预测因素。共纳入25篇文章、153例患者,CP队列132例,CIP队列21例。CP患者瘙痒数字评定量表(NRSI)从基线8.79±0.86降至最终2.32±1.27;CIP患者从8.33±0.80降至0.95±0.59。治疗4周内改善者最终NRSI降幅显著更大;有特应性病史者应答较低且结膜炎更多。

要点

  • CP患者NRSI从基线8.79±0.86降至最终2.32±1.27,CIP患者从8.33±0.80降至0.95±0.59。
  • CP患者中110/123(89%)NRSI降低>4,CIP患者100%降低>4。
  • 治疗4周内改善者最终NRSI降幅6.57±1.71,显著大于4周后改善者的5.49±1.39(P<0.001)。

核心结论

  • 度普利尤单抗可显著改善慢性痒疹和慢性特发性瘙痒患者的瘙痒症状。
  • 治疗4周内出现改善是未来应答的早期预测因素,最终NRSI降幅显著更大。
  • 有特应性病史或既往使用环孢素/甲氨蝶呤者应答较低,且更易出现结膜炎等副作用。

研究设计与样本

  • 系统文献综述,检索4个电子数据库,纳入25篇文章共153例患者。
  • CP队列132例,CIP队列21例,均为回顾性队列。
  • 主要结局为患者报告的瘙痒数字评定量表(NRSI)降低>4;次要结局包括完全应答比例、研究者全球评估(IGA)病灶数减少、睡眠数字评定量表(NRSS)改善、皮肤病生活质量指数(DLQI)改善、首次改善时间(Time-First)和瘙痒完全消失时间(Time-Final)。
  • 采用描述性统计和单因素逻辑回归分析应答与预测因素的关联。

主要发现

  • CP患者基线NRSI 8.79±0.86,最终NRSI 2.32±1.27;首次改善时间5.18±3.13周,完全改善时间13.6±12.0周。
  • CP患者中90/109(83%)在治疗4周内注意到瘙痒改善;治疗结束时18/126(14%)完全缓解,110/123(89%)NRSI降低>4。
  • CP患者中治疗4周内改善者NRSI降幅6.57±1.71,显著大于4周后改善者的5.49±1.39(P<0.001)。
  • 有特应性病史者NRSI降幅显著较低(例如非相关AD患者6.05±1.34 vs. 7.08±1.90,P<0.01)。
  • CIP患者基线NRSI 8.33±0.80,最终NRSI 0.95±0.59;首次改善时间2±0周,完全改善时间14.6±10周;治疗结束时3/21(14%)完全缓解,100%患者NRSI降低>4。

临床怎么用

  • 作者认为治疗4周内改善是度普利尤单抗未来应答的重要早期预测因素。
  • 作者指出有特应性病史或既往使用环孢素/甲氨蝶呤的患者应答较低且副作用更多。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dupilumab has demonstrated a great reduction in chronic pruritus that is the hallmark of atopic dermatitis (AD). Underscoring relevant pathogenesis similarities emerging from AD, chronic idiopathic pruritus (CIP) and chronic prurigo (CP), several authors suggested the beneficial role of dupilumab in these conditions. The evidence on this subject is limited with no precise data available. In this study, we carried out a systematic literature review in order to evaluate the efficacy of dupilumab on both pruritus and skin manifestations in the two largest retrospective cohorts of patients with CP and CIP and tried to identify potential response predictors. Electronic searches were conducted on 4 databases. Our primary outcome was the improvement in pruritus measured by a reduction in the patient's reported numerical rating scale of itch (NRSI) by >4. Secondary outcomes included the proportion of patients with a complete response at the end of treatment, reduction in the number of lesions by the Investigator Global Assessment (IGA), improvement in numerical rating scale of sleep (NRSS), improvement in quality of life measured by the Dermatology Life Quality Index (DLQI), time until patient perceived any improvement (Time-First) and time until the patient-reported absence of pruritus (Time-Final). Descriptive statistics were calculated for each demographic and clinical variable. Univariate logistic regression analyses were conducted to explore the association between response to dupilumab and potential predictive factors. We included 25 articles in the analysis, counting a total of 153 patients. Based on CP patients' cohort (n = 132), the mean NRSI at baseline was 8.79 ± 0.86 and the NRSI final was 2.32 ± 1.27. The mean time to first improvement was 5.18 ± 3.13 weeks, while the time to complete improvement of pruritus (Time-final) was 13.6 ± 12.0 weeks. Ninety patients out of 109 (83%) noticed an improvement in pruritus before 4 weeks of dupilumab therapy. At the end of treatment, 18 patients out of 126 (14%) had a complete remission of pruritus and 110 patients out of 123 (89%) had a reduction of NRSI >4. The reduction in NRSI was significantly greater in patients improving before 4 weeks of treatment (6.57 ± 1.71) compared with patients improving in more than 4 weeks (5.49 ± 1.39, P < 0.001). Patients with history of AD and those who have been previously treated with cyclosporine or methotrexate had a significantly lower reduction in NRSI (e.g. 6.05 ± 1.34 vs. 7.08 ± 1.90, P < 0.01 for nonassociated AD patients). Based on CIP patient's cohort (n = 21), the mean NRSI at baseline was 8.33 ± 0.80 and the NRSI final was 0.95 ± 0.59. The mean time to first improvement was 2 ± 0 weeks, while the time to complete improvement (Time-final) was 14.6 ± 10 weeks. At the end of treatment, 3 patients out of 21 (14%) had a complete remission of pruritus and 100% of patients had a reduction of NRSI >4. No serious treatment-emergent adverse events were reported. The most common adverse event was mild conjunctivitis (13 cases). We highlight the importance of one early sign of improvement as a predictor of the future response to dupilumab: the improvement before 4 weeks of treatment that leads significantly to a greater final reduction in NRSI. Furthermore, patients with the presence or history of atopy appear to be less responsive to dupilumab than nonatopic patients and develop more side effects, in particular conjunctivitis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gael M, Adam T, Mariano-Bourin M, et al. Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors. J Eur Acad Dermatol Venereol. 2022. PMID: 35569006. doi:10.1111/jdv.18221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。